Hepatitis Treatment News : Hep C Drugs Saddle Largest Insurer With Enormous Expense
A Smart + Strong Site
Subscribe to:
Hepatitis E-newsletter
Join Us:

Back to home » Hepatitis Treatment News » April 2014


emailprint

April 21, 2014

Hep C Drugs Saddle Largest Insurer With Enormous Expense

Hep Pill Money
UnitedHealth Group, the nation’s largest insurer, paid $100 million for hepatitis C virus (HCV) medications during the first quarter of the year, MedPage Today reports. The figure was much larger than expected and has proved a drag on the company’s stock price.

The news points to pent-up demand and the rush to access hep C treatment after the U.S. Food and Drug Administration (FDA) approved two revolutionary new drugs, Gilead Sciences’ Sovaldi (sofosbuvir) and Janssen’s Olysio (simeprevir), at the end of 2013. The drugs are each highly expensive: Sovaldi costs $84,000 and Olysio $66,000 for 12 weeks of treatment. This trend spells bad news for Medicaid and Medicare budgets as well as for the bottom lines of major private insurers that neglected to consider such costs when determining 2014 insurance premiums.

In a surprise to many, considering Sovaldi’s apparent supremacy in the market and the drug’s tendency to hog headlines, The Wall Street Journal has reported that the first quarter of the year saw $354 million in sales for Olysio. By comparison, Sovaldi sales are predicted to possibly pass the $1 billion mark during the same period.

Olysio sales may have been boosted by the American Association for the Study of Liver Diseases’ recommendation that those with genotype 1 of hep C who are interferon intolerant receive 12 weeks of therapy with Sovaldi, Olysio and ribavirin. Otherwise, Sovaldi is the recommended therapy.

To read the MedPage Today story, click here.

To read the Wall Street Journal story, click here.

Search: Hepatitis C, virus, HCV, hep C, UnitedHealth Group, Sovaldi, sofosbuvir, Olysio, simeprevir, Janssen, Gilead Sciences, The Wall Street Journal, MedPage Today.


Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
Current Issue
Forums
Poll
Blogs
Hep TV
Calendar
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
Transmission
Prevention
Treatment
• Hepatitis B
Transmission
Prevention
Treatment
• Hepatitis C
Transmission
Prevention
Treatment
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
TALK TO US
Tell us what you think
Poll
Are you planning to do anything for World Hepatitis Day on July 28?
Yes
No


Survey
Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.